Related Experiment Video
Updated: Apr 30, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Recent advances in the treatment of gastrointestinal stromal tumors
César Serrano1, Suzanne George2
1Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, USA cserrano2@partners.org.
Abstract:
Constitutively activating mutations in the KIT and platelet-derived growth factor receptor α (PDGFRA) RTKs play a crucial role in the biology of gastrointestinal stromal tumors (GISTs), and this disease has served as an effective model for targeting gain-of-function kinase mutations in cancer. Imatinib has entered the clinical arena in the last decade and substantially improved the outcome in these formerly untreatable cancers. However, most advanced GISTs responding to imatinib progress within 2-3 years due to heterogeneous subclones harboring a range of imatinib-resistant secondary KIT mutations. Sunitinib, and more recently, regorafenib, have obtained US Food and Drug Administration approval for the treatment of GISTs after imatinib failure, and thus expanded the treatment options in resistant disease. Within this framework, we present an evaluation of current GIST management, emphasizing the most recent advances in the field together with a discussion on future steps to be taken in refractory disease.
Insights
Gastrointestinal stromal tumors (GISTs) are driven by KIT and PDGFRA mutations. While imatinib is effective, resistance develops, necessitating newer therapies like sunitinib and regorafenib for advanced GIST.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gastrointestinal stromal tumors (GISTs) are driven by activating mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptor tyrosine kinases (RTKs).
- Targeting these oncogenic driver mutations has revolutionized GIST treatment, with imatinib significantly improving outcomes.
Purpose of the Study:
- To review current management strategies for GIST.
- To highlight recent therapeutic advances and discuss future directions for refractory GIST.
Main Methods:
- Literature review of GIST treatment, focusing on targeted therapies.
- Analysis of treatment outcomes and resistance mechanisms.
Main Results:
- Imatinib therapy is highly effective but often followed by acquired resistance due to secondary KIT mutations.
- Subsequent therapies including sunitinib and regorafenib have been approved for imatinib-resistant GIST.
Conclusions:
- Despite advances, acquired resistance remains a challenge in GIST treatment.
- Ongoing research is crucial for developing novel strategies against refractory GIST.
More Related Videos
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...